ATE508738T1 - System zur beabstandeten abgabe von arzneimitteln - Google Patents

System zur beabstandeten abgabe von arzneimitteln

Info

Publication number
ATE508738T1
ATE508738T1 AT06019650T AT06019650T ATE508738T1 AT E508738 T1 ATE508738 T1 AT E508738T1 AT 06019650 T AT06019650 T AT 06019650T AT 06019650 T AT06019650 T AT 06019650T AT E508738 T1 ATE508738 T1 AT E508738T1
Authority
AT
Austria
Prior art keywords
drug delivery
delivery system
present
provides
patient
Prior art date
Application number
AT06019650T
Other languages
English (en)
Inventor
Dilip Shantilal Shanghvi
Kirti Wardhaman Ganorkar
Yashoraj Rupsinh Zala
Nitin B Dharmadhikari
Satish C Khanna
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN37MU2001 external-priority patent/IN191539B/en
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Application granted granted Critical
Publication of ATE508738T1 publication Critical patent/ATE508738T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT06019650T 2001-01-12 2002-01-11 System zur beabstandeten abgabe von arzneimitteln ATE508738T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN37MU2001 IN191539B (de) 2001-01-12 2001-01-12
IN323MU2001 2001-04-10
IN326MU2001 2001-04-10
IN324MU2001 2001-04-10
IN325MU2001 2001-04-10

Publications (1)

Publication Number Publication Date
ATE508738T1 true ATE508738T1 (de) 2011-05-15

Family

ID=27517736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06019650T ATE508738T1 (de) 2001-01-12 2002-01-11 System zur beabstandeten abgabe von arzneimitteln

Country Status (9)

Country Link
US (2) US7964216B2 (de)
EP (2) EP1349531A1 (de)
JP (1) JP4633329B2 (de)
AT (1) ATE508738T1 (de)
BR (1) BRPI0206432A2 (de)
CA (2) CA2434169C (de)
MX (1) MXPA03006217A (de)
PL (1) PL362687A1 (de)
WO (1) WO2002055009A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP1945189A4 (de) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd Beschichtete tabletten mit verlängerter magenretention
EP2026787B1 (de) * 2006-05-13 2013-12-25 Novo Nordisk A/S Repaglinid und metformin enthaltende tabletten-formulierung
CA2672602C (en) 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
CA2677623C (en) 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
HK1214966A1 (zh) * 2013-01-05 2016-08-12 Anji Pharmaceuticals Inc. 包含雙胍的延遲釋放組合物
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
CN104621714B (zh) * 2014-12-04 2018-01-05 湖北中烟工业有限责任公司 一种提高脆性的烟用添加剂滴丸及其制备方法
CN110882261A (zh) * 2019-12-27 2020-03-17 无锡福祈制药有限公司 二甲双胍格列吡嗪制剂
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
DE2021147A1 (de) * 1970-04-30 1971-11-11 Christian Brunnengraeber Chem Kapsel mit einer Fuellung von Pharmazeutika
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
US4252786A (en) 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
JPS60241871A (ja) * 1984-05-16 1985-11-30 Ajinomoto Co Inc アスパルテ−ム含有崩壊錠剤の製造法
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3629994A1 (de) 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4976967A (en) 1987-08-03 1990-12-11 Merck & Co., Inc. Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
GB8913889D0 (en) * 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
EP0408496A3 (en) 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
US5226902A (en) * 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
MX9205850A (es) * 1991-10-10 1993-06-01 Alza Corp Dispositivos de surtido osmotico de farmaco con materiales de pared hidrofobicos
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
WO1993012765A1 (en) 1991-12-27 1993-07-08 Merck & Co., Inc. A controlled release drug dispersion delivery device
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
ATE201139T1 (de) 1997-06-13 2001-06-15 Novo Nordisk As Neue dosierung für diabetes type 2
CN1114404C (zh) 1997-06-18 2003-07-16 史密丝克莱恩比彻姆有限公司 用噻唑烷二酮和二甲双胍治疗糖尿病
CN1168451C (zh) 1997-06-18 2004-09-29 史密丝克莱恩比彻姆有限公司 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
ATE238774T1 (de) 1997-10-09 2003-05-15 Dexcel Pharma Technologies Ltd Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP1039890B1 (de) 1997-12-08 2004-03-17 Bristol-Myers Squibb Company Neue metformin salze und verfahren
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2000025757A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Sustained release delivery of highly water-soluble compounds
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
EA007610B1 (ru) * 1998-11-12 2006-12-29 Смитклайн Бичам Плс Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
EP1165054A4 (de) * 1999-04-06 2005-02-09 Pharmaquest Ltd Pharmazeutische darreichungsform zur gepulsten verabreichung von methylphenidat
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
CA2378829A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Sustained release drug dispersion delivery device
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1095650A1 (de) 1999-10-29 2001-05-02 Universiteit Leiden Zweiphasensystem mit kontrollierter Freigabe
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20040156900A1 (en) 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system

Also Published As

Publication number Publication date
EP1738751A2 (de) 2007-01-03
US20040086562A1 (en) 2004-05-06
EP1349531A1 (de) 2003-10-08
PL362687A1 (en) 2004-11-02
EP1738751A3 (de) 2007-01-17
BRPI0206432A2 (pt) 2016-10-25
US7964216B2 (en) 2011-06-21
US20110250271A1 (en) 2011-10-13
CA2434169C (en) 2011-03-15
MXPA03006217A (es) 2004-10-15
JP2004523510A (ja) 2004-08-05
WO2002055009A1 (en) 2002-07-18
EP1738751B1 (de) 2011-05-11
CA2725833A1 (en) 2002-07-18
JP4633329B2 (ja) 2011-02-16
CA2434169A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
ATE508738T1 (de) System zur beabstandeten abgabe von arzneimitteln
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
IL208184A0 (en) Glp-1, and methods for treating diabetes
BR9906813A (pt) Método para administração de insulina aspb28- humana
ATE468845T2 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
DE602004026701D1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
ATE99941T1 (de) Medikamente enthaltend salmeterol und fluticason.
MXPA05012810A (es) Formas de dosis oral de memantina.
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
DE60015560D1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
DK0559145T3 (da) Lægemiddel til truende abort
RU96115219A (ru) Способ лечения больных сахарным диабетом
DE60111919D1 (de) Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
JP2004503471A5 (de)
Fu et al. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients
RU2004116492A (ru) Способ профилактики реперфузионных осложнений при турникетной травме
Cadman Set back for nerve growth factor
MD1780G2 (ro) Metodă de tratament al pacienţilor cu ciroze hepatice
DE602004016128D1 (de) Verwendung von löslichem cd14 zur behandlung von erkrankungen
TH50374A (th) วิธีการสำหรับการป้องกันโรคอุจจาระร่วง
RU2004130270A (ru) Способ коррекции гипоксических нарушений при деструктивных формах острого панкреатита
WO2003080037A3 (de) Verwendung von ltb4 antagonisten in der tiermedizin
RU2002101630A (ru) Способ лечения эндометрита у коров

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties